The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Open accessAbstract
INTRODUCTION: Current drugs for the treatment of psychiatric or neurodegenerative disorders have limitations. Psychotherapeutic drugs such as typical and atypical antipsychotics, tricyclic antidepressants and selective monoamine reuptake inhibitors, aim to normalize the hyper- or hypo-neurotransmission of monoaminergic systems. Despite their contribution to the outcomes of psychiatric patients, these agents often exert severe side effects and require chronic treatments to promote amelioration of symptoms. Drugs available for the treatment of neurodegenerative disorders are severely limited. AREAS COVERED: Recent evidence that has shed light on sigma-1 receptor ligands, which may serve as a new class of antidepressants or neuroprotective agents. Sigma-1 receptors are novel ligand-operated molecular chaperones regulating signal transduction, ER stress, cellular redox, cellular survival and synaptogenesis. Selective sigma-1 receptor ligands exert rapid antidepressant-like, anxiolytic, antinociceptive and robust neuroprotective actions in preclinical studies. Recent studies that suggest that reactive oxygen species might play a role as signal integrators downstream of Sig-1Rs are also covered. EXPERT OPINION: The advances in sigma receptor research in the last decade have begun to elucidate the intracellular signal cascades upstream and downstream of sigma-1 receptors. The novel ligand-operated properties of the sigma-1 receptor chaperone may enable interventions by which stress-related cellular systems can be pharmacologically controlled.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654
Self-citationFibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Double-blind treatment of major depression with dehydroepiandrosterone.
Wolkowitz, O. M., Reus, V. I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L., & Roberts, E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.646 · Cited by 411 · cited 2×
“The efficacy of Sig-1R agonists or antidepressants with Sig-1R affinity in the treatment of affective disorders or related symptoms Igmesine (CL-1019, JO-1784) Open III (discontinued) Yes (18/30) [114] DBT, RCT No [114] Opipramol DBT, RCT Clinically used Yes (63/100) [100]* DBT, RCT Yes [140]z Fluvoxamine DBT Clinical…”
BackgroundSynapse Pathology in Psychiatric and Neurologic Disease
van Spronsen, M., & Hoogenraad, C. C. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0104-8 · Cited by 345
Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease
Zaja-Milatovic, S., Milatovic, D., Schantz, A. M., Zhang, J., Montine, K. S., Samii, A., Deutch, A. Y., & Montine, T. J. (2005) · Neurology · doi:10.1212/01.wnl.0000150591.33787.a4 · Cited by 300
Dehydroepiandrosterone treatment of midlife dysthymia∗∗See accompanying Editorial, in this issue.
Bloch, M., Schmidt, P. J., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00066-9 · Cited by 179
Low density of sigma1 receptors in early Alzheimer’s disease
Mishina, M., Ohyama, M., Ishii, K., Kitamura, S., Kimura, Y., Oda, K.-I., Kawamura, K., Sasaki, T., Kobayashi, S., Katayama, Y., et al. (2008) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0094-z · Cited by 172 · cited 1×
“A binding assay using post-mortem brains and PET scans suggested the decrease of sigma-binding sites in brains with Alzheimer’s disease [86,120].”
MethodThin, Stubby or Mushroom: Spine Pathology in Alzheimers Disease
Tackenberg, C., Ghori, A., & Brandt, R. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486554 · Cited by 112
Cited by
The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems
Su, T.-P., Su, T.-C., Nakamura, Y., & Tsai, S.-Y. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.003 · Cited by 320
Self-citationThe sigma-1 receptor: roles in neuronal plasticity and disease
Kourrich, S., Su, T.-P., Fujimoto, M., & Bonci, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.09.007 · Cited by 245
Self-citationPathological overeating: emerging evidence for a compulsivity construct
Moore, C. F., Sabino, V., Koob, G. F., & Cottone, P. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.269 · Cited by 126
Fluvoxamine alleviates ER stress via induction of sigma-1 receptor.
Omi, T., Tanimukai, H., Kanayama, D., Sakagami, Y., Tagami, S., Okochi, M., Morihara, T., Sato, M., Yanagida, K., Kitasyoji, A., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.301 · Cited by 113
Hayashi, T. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12262 · Cited by 87
Self-citation
Metadata
- Authors
- Hayashi, T., Tsai, S.-Y., Mori, T., Fujimoto, M., & Su, T.-P.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2011-03-05
- Volume
- 15
- Issue
- 5
- Pages
- 557-577
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1981373150
- Cited by
- 204
- References
- 9
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. https://app.cochat.ai/papers/10.1517/14728222.2011.560837
- The paper
- Hayashi, T., Tsai, S.-Y., Mori, T., Fujimoto, M., & Su, T.-P. (2011). Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2011.560837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
